Opioidergic pain relief in humans is mediated by beta and high-gamma modulation in limbic regions

Jacob C. Garrett,[1][†] Sierra Wilson,[1] Alexander Jessup,[2] Michael G. Brandel,[3] Caleb S. Nerison,[4] Ahmed M. Raslan,[5] Sharona Ben-Haim,[3]* Eric Halgren[6]*

Abstract

The nature of the neurophysiological effects of opioids, especially those responsible for their analgesic properties, are unknown, hindering efforts to develop non-addictive alternatives. Fentanyl and hydromorphone were administered to patients experiencing semi-chronic, clinically-relevant pain after surgical implantation of electrodes for the localization of seizure onset. Opioids suppressed beta oscillations in lateral amygdala, ventral and dorsolateral prefrontal cortices, and increased beta in medial amygdala and hippocampus. Opioids also suppressed high gamma oscillations in insula and lateral amygdala, and increased high gamma in cingulate cortex and hippocampus. The amplitude of these beta effects in the ventral prefrontal cortex, medial amygdala and hippocampus, and of gamma effects in the insula, were positively correlated with the magnitude of pain relief in response to a constant dose. These findings identify electrophysiological events in a network of limbic structures that may participate in opioidergic pain relief through nociceptive gating and a decreased concerned fixation on pain, providing insights into the neural basis of pain relief and suggesting possible biomarkers for developing non-addictive opioid alternatives.

[1]Neurosciences Graduate Program, University of California, San Diego, La Jolla, California, USA.

[2]Scintillion Institute, San Diego, California, USA

[3]Department of Neurological Surgery, University of California, San Diego, La Jolla, California, USA

[4]Department of Family Medicine, Lexington Medical Center, West Columbia, South Carolina, USA

[5]Department of Neurological Surgery, Oregon Health & Science University, Portland, Oregon, USA

[6]Departments of Radiology & Neuroscience, University of California San Diego, La Jolla, California, USA

[†]Corresponding author

*Equal contribution

Introduction

Little is known about the neural basis of analgesia for clinically relevant pain in the human forebrain. Studies conducted to date have typically evoked acute pain in their experimental paradigms, which lacks qualities including the persistence, and associated distress, of more representative pain requiring medical management. Aside from its sensory-discriminative properties, human pain requiring clinical treatment is also an affective and interpretive phenomenon[31,39,70], and far less is known about these higher order telencephalic pain substrates. To further examine these substrates, we utilized the precision and sensitivity of bipolar intracranial recordings to measure the effects of opioids in the human brain and isolate signatures of opioidergic analgesia.

Intracranial evoked potentials and high-frequency activity following acute experimental pain have been reported previously.[6,7,11,20,25,38] Generally, these studies have observed responses in primary somatosensory cortex, in insular cortex, anterior cingulate and other limbic regions, which is consistent with known telencephalic pain pathways.[11] Three complementary studies by the same research group characterized the temporal sequence of evoked potentials across the brain, demonstrating a progression from sensory to associative regions, notably involving the medial temporal lobe later than cortical regions.[6,7,25] While most evoked pain studies have not dissociated nociception from sensory effects per se, one study tested correlates of gradations in rated thermal pain level while controlling for stimulus temperature, and found that anterior cingulate, hippocampus, frontal regions, striatum, amygdala, and fusiform gyrus predicted pain ratings.[11]

Notably, a recent study used machine learning to classify endogenous variations in intensity of pain in patients with refractory neuropathic pain.[62] This was successful in predicting high pain significantly above chance; however, this model utilized only a limited set of brain regions and did not attempt to identify LFP signatures which were consistent across subjects. Machine-learning based approaches have also been successful at predicting chronic pain status[37] and endogenous variation in chronic pain state[57] using scalp EEG. These methods have potential clinical applications in diagnosis or monitoring and demonstrate that EEG contains information relevant to pain state; however, they do not easily generalize to clinically relevant models of pain or pain relief.[56]

There have been, to date, no peer-reviewed human studies which have uncovered consistent neural signatures of opioid effects on human local field potentials, and few studies of any methodology on the correlates of pain relief in human brain, none on clinically

relevant pain. Most studies on pain processing in humans have employed transient (typically seconds) and non-destructive heat or shock stimuli. Patients undergoing epilepsy monitoring with depth electrodes often have a significant degree of post-surgical pain, which is commonly treated with intravenous opioid drugs at various points during the recording period. Sites sampled frequently for the purposes of epilepsy monitoring include regions having well-established associations with pain, including insula, ventral prefrontal cortex, amygdala, and hippocampus. This presents an opportunity to study the forebrain neural signatures of clinically relevant pain relief with the precision of intracranial depth electrode recordings, providing novel insight into final pathways of pain processing, as well as forebrain mechanisms of pain relief.

Materials and methods

Patient population

The participants gave written informed consent to participate in this study, and the study was approved by University of California's Institutional Review Board in accordance with the Declaration of Helsinki. The participants were compensated for their participation. Patients were recruited from a population with long-standing drug-resistant complex partial epilepsy who are implanted with depth electrodes in order to determine their seizure origin. While awaiting spontaneous seizures to occur, the patients may consent to participate in experiments. Regions of the frontal lobe and limbic system are frequently and consistently implanted for the purposes of epilepsy monitoring and are also locations that are implicated in the affective-interpretive aspects of pain. Patients often experience some degree of post-surgical pain as a consequence of the surgical implantation procedure. We identified patients who experienced significant pain and received pain-relieving opioid medication. A subset of four patients (of 26 for which data were available) were given at least 10 doses of intravenous opioids which did not coincide with putative sleep or (post-)seizure periods (defined below); these were chosen for further analysis (see Table 1). All patients had overall cognitive function in the normal range.

Data preprocessing

Archival SEEG recordings were processed and reformatted for analysis using standard methods. A notch filter was applied at 60 Hz line noise frequency and its harmonics up to the

Nyquist frequency, before the data was resampled to a uniform 1000 Hz sampling rate, from native sampling rates of 500-1024 Hz, using a delay-compensated FIR antialiasing filter. To ensure that measured signals were focal, all monopolar recordings were bipolar re-referenced, utilizing adjacent depth electrode contacts with 5 mm pitch. Bipolar pairs were excluded if displaying low amplitude (indicating white matter or CSF, approximate threshold of 30 µV slow-wave amplitude), abnormal LFP (e.g. prominent atypical oscillations), frequent interictal discharges (>3 min^{-1} in cortex or 1 min^{-1} in medial temporal lobe), or if located within a seizure focus. Time series analysis was performed using custom MATLAB code and FieldTrip.[75]

All cortical bipolar pairs were selected from non-overlapping contacts; however, due to the limited number of high-quality channels in hippocampus and amygdala, overlap was allowed in these regions.Electrode location was determined by MRI/CT co-registration, followed by automated parcellation using FreeSurfer[23,24] and the HCP-MMP1[29] cortical segmentation. In one patient (P3) where surface reconstruction was not possible due to incomplete imaging data, electrode locations were hand-annotated using trajectories drawn from clinical neurosurgery software (ROSA). HCP-MMP1 parcels were aggregated to form regions of interest for cross-subject analysis and localization of opioid effects (Figure S1, Table S4). Electrodes in medial temporal structures were hand-annotated using co-registered MRI and CT scans in 3D Slicer.[36]

Epoch selection and artifact rejection

Interictal epileptiform events (spikes) were detected as described previously:[18,19] A high frequency score was computed by smoothing the 70-190 Hz analytic amplitude with a 20 ms boxcar function and a spike template score was generated by computing the cross-covariance with a template interictal spike. Both scores were normalized by their channel-wise medians. The high frequency score was weighted by 13 and the spike score was weighted by 25, and an IIS was detected when these weighted sums exceeded 130. In each patient, detected IIS and intervening epochs were visually examined from all channels to confirm high detection sensitivity and specificity. The detected period, 300 ms preceding, and 700 ms following were excluded from further analysis. Putative seizures were marked as unusually sudden and dense periods of epileptiform activity (detected as above), cross-referenced with clinical records, and visually confirmed in the raw LFP. The durations of all seizures, the 5 minutes preceding, and a period of 2 hours following were excluded from analysis. The latter value

was chosen to reliably exceed the length of time required for spectral amplitude measures (e.g. high-gamma (HG) 70-190 Hz envelope, suppressed post-seizure, and slow-wave 0.5-2 Hz envelope, amplified post-seizure) to return to baseline. Epochs containing large artifacts, interruptions in signal, or highly unstable spectral characteristics (assessed by beta, HG, slow-wave, 8-12 Hz alpha, and 4-8 Hz theta amplitudes) suggestive of abnormal activity, for example during an extended period of repeated seizures, were similarly identified and excluded.

Sleep rejection

Sleep rejection methodology performed as described previously,[19] consistent with criteria for N2/N3 identification described by Silber et al.[63] The median slow-wave (0.5-2 Hz) analytic amplitude across channels was used as a slow-wave sleep score to identify and exclude sleep. Slow-wave sleep cycles were detected as periods in which the slow-wave sleep score was greater than three times the median of the score over the preceding 18 through the following 18 hours. The use of the local median allowed correction for amplitude drift during the recording. 25 minutes preceding or following slow-wave sleep peaks thus defined were excluded to ensure that N1 and REM periods were also eliminated.

Testing of drug effect

Administration times of intravenous opioid medications were recorded with minute-scale precision as a function of clinical recordkeeping. We compared neurophysiological metrics during the period immediately preceding administration of an opioid to a period of expected peak analgesic effect (10-30 minutes) for both intravenous fentanyl and hydromorphone.[13,15] All opioid doses were separated by at least 60 minutes.

Spectral perturbation plots

Event-related spectral perturbation plots were generated using power spectra computed for each minute of data. Each minute of data was segmented into continuous non-overlapping segments of at least 8 seconds without detected IIS or artifacts, and the average of all such segments taken as the spectrum of the corresponding minute. A multi-taper time-frequency spectral estimation method was employed, as implemented in the Chronux[12,45] toolbox. Resultant spectra were resampled from linear to log-frequency scales while applying a delay-

compensated finite impulse-response antialiasing filter. Drug-evoked changes were normalized to the pre-drug (30-10 minute) baseline period. For event-related spectral perturbation (ERSP) plots (Fig. 1A), the mean spectral response across trials was expressed in dB for each minute interval relative to drug dose. For spectral change plots (Fig. 1B), the average spectral power from 10-30 minutes post-drug was normalized to the pre-drug baseline, and the result expressed as a raw proportion. Results were smoothed for display using a Gaussian filter over time (ERSP) and frequency (ERSP and spectral change plots).

Evoked amplitude-modulation plots

Drug-evoked changes in beta or high-gamma amplitude were further analyzed by applying a third-order Butterworth bandpass filter to isolate the corresponding frequency (15-25 Hz or 70-190 Hz, respectively), and computing the exact Hilbert analytic amplitude.[41] In order to eliminate the potential effects of long-term drifts in spectral characteristics, the amplitude time-course for each trial was baselined and normalized by the mean and variance, respectively, of the baseline period (30 to 10 minutes prior to each dose) for that trial. Trials were rejected if more than 75% of the baseline period was rejected (see above, **Epoch selection and artifact rejection**, and **Sleep rejection)** or more than 25% of the effect averaging period was rejected. Channels were pooled within predefined regions of interest, which were chosen according to sampling, known neurophysiology of pain, and conventional neuroanatomical distinctions. The z-score of the drug effect, defined as the average of the above timecourses within the 10-30 minute window following each drug dose, was computed for each recording site, and used for cross-site analyses.

Site-wise pain-relief correlation estimates

To assess the neural correlates of pain relief, change in VAS score pre-to-post opioid was compared to change in measures of interest (beta or high-gamma analytic amplitude, computed as described above, **Testing of drug effect**) 30 to 10 minutes pre-opioid to the 10 minutes preceding the post-opioid pain measurement. Only trials in which the modal dose of opioid was given were included. Further, doses were excluded if the most recent pre-drug VAS rating was more than 20 minutes prior to drug dose, or if the soonest post-drug VAS rating was less than 20 or more than 90 minutes post-drug. Each trial was normalized to its baseline mean and variance, as above, to account for long-term shifts. For each recording site,

the R value of the correlation between VAS change and neurophysiological change was computed and used for cross-site analyses.

Cross-site drug-effects and pain relief models

Separate models were employed for each combination of frequency (beta/HG) and analysis type (drug effect/pain relief) in order to assess overall and regional patterns in drug-effect or pain-relief signatures. A linear mixed model, including a random effect on intercept by subject was employed to account for within-subject correlations. Z-scores (drug effect) or R values (pain-relief correlations) were modeled as a function of drug type, hemisphere, and region as categorical covariates. To further control for heterogeneity across time in the clinical environment, we also modeled single trial responses as a function of brain region and hemisphere, with trial and subject as random effects on the intercept.

Finally, linear models were designed to test the association between sites of opioid action and pain relief, separately for beta and high-gamma frequency effects. For each frequency, pain-relief R values were modeled as a linear function of drug-effect Z-values, while including categorical covariates for each subject. In this case, the intercept was constrained to zero, the expected value of both variables.

Control analysis of non-opioid nurse check-ins

We verified that observed neurophysiological effects were not the caused by interactions with nurses per se by applying the same analysis used for testing IV opioid-evoked effects to non-opioid nurse check-ins. These were events in which the nurse similarly interacted with the patient and the patient reported a VAS score, but opioids were not given. Furthermore, we restricted our analysis to cases where no opioid had been given for 90 minutes, nor was any opioid given for at least 30 minutes (the end of the post-event averaging period) afterward. Note that such interactions may have resulted in a pain drug being given (e.g. acetaminophen) or a non-pain-related medication, but did not result in an opioid being given (e.g. oral oxycodone or any IV opioid). As with our analysis of IV opioid effects, we conducted an analysis using a linear-mixed effects model to test for any overall changes in beta or HG amplitude associated with such events, as well as any region-wise or hemispheric variation.

Results

Spectral characterization of opioid-evoked responses

Recordings from bipolar channels were examined in their responses to opioids across time and frequency. Sites from all subjects exhibited pronounced suppression in the 15-25 Hz beta frequency range (Fig. 1A). The period 10-30 minutes post-opioid was chosen to measure drug effect, as this falls within the period of peak pain relief for both drugs;[13,15] this period captured the distinct suppression of beta-frequency amplitude (Fig. 1B). Nevertheless, we observed that the time-course of the drug effect matched the kinetics of either the short-acting (fentanyl, FENT) or longer-acting (hydromorphone, HMOR) opioid (# of sites significant at 30-50 minutes: 2 of 23 active FENT sites, 14 of 31 active HMOR sites, site-wise effects FDR corrected $p < 0.05$, chi squared test by drug and duration $p = 0.004$).

Regional characteristics of opioid-induced beta suppression

Opioids strongly and rapidly suppressed in beta-frequency amplitude on average in all four subjects (Fig. 2A). This effect was frequently significant in single-site average responses (Fig. 2B). When site-wise responses are plotted on a common reference brain, there appears to be a gradation in which more frontal sites exhibit greater beta suppression (Fig. 2C). Beta suppression was present in both hemispheres, and similar between FENT and HMOR (Fig. 2D). A linear mixed-effects model of site-wise average responses revealed a significant overall suppression of beta amplitude by opioids, as well as significant relative suppression in Ventral Prefrontal Cortex (VPFC) and Dorsolateral Prefrontal Cortex (DLPFC) among cortical regions (see corresponding section of Table 2).

A functional division within the amygdala is demonstrated in a series of sites from one subject (P1): MAmyg exhibits exclusively a transient beta facilitation from 5-10 minutes post-drug, whereas in Lamyg FENT reduced beta amplitude for approximately 30 minutes (Fig. 3A). These sites were arrayed along a single depth electrode, spanning the full medial-lateral axis of the amygdala (Fig. 3B). Responses in hippocampus were variable, but tended to be increases rather than decreases (Fig. 3C). Significantly higher beta post-opioid, relative to the main effect, was present in medial amygdala, and both anterior and posterior hippocampus (see Table 2).

High-gamma amplitude modulation by opioids

In contrast to broad beta suppression, high-gamma (HG) amplitude showed no overall trend following administration of opioids. However, site- and region-specific effects were apparent. Opioids suppressed HG in a subset of cortical sites, while both HG facilitation and suppression were evoked in medial temporal sites (Fig. 4A). HG amplitude was generally suppressed in Insula (INS) and in LAmyg. Again, other medial temporal structures (MAmyg, AHC, PHC) tended to respond oppositely to LAmyg, with significant increases in both AHC and PHC (Fig 4B, Table 2). High-gamma amplitude in cingulate also tended to increase following opioids; visual inspection of sites reveals that this is driven by evoked HG in a mid-posterior cingulate subpopulation. Finally, whereas HMOR and FENT produced similar beta suppression, fentanyl was associated with lower HG amplitude than HMOR (Fig. 4C), though this may be influenced by subject heterogeneity.

Neural correlates of opioid analgesia

In order to dissociate nontherapeutic effects of opioid medication and probe for neural signatures specific to pain, we tested for correlations between beta or HG amplitude and endogenous variability in reported pain relief, while holding opioid dose constant. Amplitude changes were measured between the 30-10 minute pre-drug baseline and the 10 minute period preceding the post-drug pain evaluation. The R value of the correlation between change in beta or HG and change in pain score was calculated for each site. In medial temporal regions, pain relief broadly appears more frequently associated with beta or HG increases than decreases (Fig. 5A); this was significant for beta amplitude in both MAmyg and AHCamplitude, and HG in MAmyg (Table 2). Region-wise pain-relief correlates also broadly aligned with the effects of opioids: besides enhancement of beta in Mamyg and AHC, suppression of beta in VPFC, and suppression of HG in INS expected to correlate with pain relief (Fig. 5B, Fig. 6). Interestingly, a brain-wide effect for beta amplitude was significant, though of modest effect size; decreases in beta are on average associated with pain relief. Finally, beta amplitude in INS and HG in VPFC also correlated negatively with pain relief. Drug type was a significant factor in the HG pain-relief model; this may represent a partial loading of subject variance. To test whether the overall pattern of drug-evoked beta or high-gamma modulation overall predicted pain relief, we modeled site-wise R values for the correlation of beta or HG change and pain relief, using the drug-effect z-score as an independent variable, and including random effects by subject to account for heterogeneity.

Coefficients for R value conditional on z-score in both the beta (0.13, p=0.001) and HG (0.09, p=0.04) models were positive and significant (Table S1), indicating that the patterns of opioid effects on beta and HG were overall significantly associated with pain relief.

Controls for nurse interaction and trial heterogeneity

We conducted analogous testing of nurse interactions which were not associated with opioid doses to verify that neurophysiological changes were not the result of social interaction, VAS score reporting, or other covariates of clinical care. No region-wise or overall effects observed peri-opioid were also evoked by nurse check-ins (Table S2). In order to account for any variability between trials that resulted from uncontrolled aspects of the clinical environment, we also modeled opioid effects at the level of single trials, correcting for random trial-wise variability shared across channels. All effects observed in our channel-wise model were robust to this control (Table S3).

Discussion

The present study represents, to our knowledge, the first characterization of the neurophysiological effects of opioids using intracranial EEG in humans, and is amongst the first efforts to isolate the neural correlates of pain relief in EEG generally, which has otherwise only been attempted in neuroimaging studies.[1,35,52] Though preliminary, these findings provide novel insight into the therapeutic effects of opioids beyond early sensory systems, on substrates of the interpretive and affective processes responsible for the psychological impact of pain.

The effects of opioids have been extensively studied in afferent nociceptive pathways. However, while the μ-opioid receptor is highly expressed in amygdala, anterior hippocampus, anterior cingulate cortex, orbitofrontal cortex, and insula,[50] the mechanisms by which opioids produce their effects in telencephalic structures are poorly understood. On a cellular level, μ-opioid receptors act upon a diverse array of cell types, often exerting its effects as a presynaptic receptor reducing neurotransmitter release. Previous studies suggest that pyramidal neurons in cortical regions are, in general, inhibited, whereas in medial temporal lobe, the effect of opioids on neural firing varies sharply by region and context.[54,81] Human neuroimaging studies on the effects of intravenous opioid drugs have produced conflicting results. Studies employing measures sensitive to blood flow (PET rCBF or BOLD fMRI) have generally found increases, most consistently in anterior cingulate, but including

other structures such as caudate nucleus, thalamus, and amygdala,[1,49,55,86] In contrast, the only fluorodeoxyglucose PET study to date found mostly decreases in many of the same structures.[58] Studies employing measures dependent on blood flow may be confounded by opioid effects on vascular dynamics or cellular metabolism.[70,92]

In transient, experimenter-evoked pain paradigms, non-invasive magnetoencephalography (MEG) and EEG studies most commonly report that signals predictive of a "high pain" state have been a decrease in central alpha band power (8-12Hz)[4,68,78] and an increase in parietal, prefrontal and thalamic gamma band power (>30Hz).[20,53,94,109] In the prefrontal cortex, tonic experimental noxious stimulation has been associated with enhanced power of gamma oscillations, and suppression of alpha and beta oscillations associated with pain intensity.[52,79,88] While acute experimental pain is sometimes associated with beta suppression in scalp EEG, studies on chronic pain have revealed a positive association between frontal beta oscillation power and pain severity in arthritic pain[96] as well as enhanced beta coherence in fibromyalgia.[2] Cross-sectional studies on neuropathic pain have identified increases in power in alpha-beta range.[26,97] A systematic review of EEG and MEG studies have concluded that enhanced beta and theta oscillations are characteristic of chronic pain generally.[108] Moreover, an EEG study in healthy patients have found decreases in beta and alpha power with moderate doses of an oral opioid.[14]

In the present study, ppioids induced a widespread reduction in beta-frequency amplitude, most prominent in the prefrontal cortex, as well as suppression of high-gamma amplitude in the insula. Effects in medial temporal lobe were mixed, with suppression of beta and HG in lateral amygdala, but relative increases in medial amygdala (beta) and hippocampus (beta and high-gamma). We compared changes in beta and HG amplitude between equal opioid doses that resulted in variable levels of pain relief, in order to determine which, if any, opioid effects were specifically predictive of pain relief. Such effects included beta decreases in VPFC, HG suppression in insular cortex, and beta increases in medial amygdala and hippocampus. Critically, there were significant positive correlations between the effects of opioids and the signatures of pain relief in both beta and high-gamma amplitudes, lending further support to the interpretation that the neural processes indexed by beta and HG play a broad role in opioidergic pain relief. Our findings are consistent with prior work indicating that the aforementioned regions, as well as the beta frequency band in which we observed the most consistent opioid effects, are implicated in pain processing, particularly in clinically relevant pain models.[27,72]

Pain-specific responses, dissociated from neutral sensory stimulation and proportional to intensity,[14] have been observed in both anterior[34] and posterior insula,[25,42] in studies utilizing both iEEG and fMRI. Models of cortical pain processing in which the posterior insula is often considered as the central hub for sensory processing of painful stimuli,[27,54,60] whereas the anterior insula has been associated with pain salience.[63,64] Consistent with these findings, we observed a tendency for opioids to suppress high-gamma amplitude in the insula, as well as a correlation between high-gamma suppression and pain relief. These findings consistently demonstrate that opioids may have a direct, blunting effect on the sensation of pain.

Persistent and distressing pain which requires clinical treatment is a complex experience dominated by its interpretive and affective components.[31,39,70] Such interpretive 'top-down' processing is often associated with beta oscillations in PFC[3] with ventral PFC supporting more affective evaluations.[16,58,59] Specifically, spontaneous fluctuations in chronic pain are associated with medial and ventral PFC fMRI-BOLD activation.[4,5,28] VPFC lesions alter the influence of expectancy on pain perception (medial regions),[47] and VPFC activation represents the relative valuation of acute painful stimuli.[71] Accordingly, in VPFC, we found that beta oscillations, rather than high-gamma, were associated with opioidergic pain relief. Beta oscillations are consistently found in chronic pain conditions, particularly in frontal regions,[2,17,64,65,72] which may reflect a transition from a naïve bottom-up form of pain-processing to one in which subjective pain is magnified by concerned fixation.[55] If so, beta suppression, as observed in the present study, would suggest relief from distress due to the capture of attention by pain.

Recent research has implicated hippocampus in the processing of pain and especially in the development of inflammatory or chronic pain-like conditions.[30,66] In humans, chronic pain is associated with reduced hippocampal gray matter volume,[48,51] and increases in total hippocampal volume have been observed in patients undergoing non-pharmaceutical treatment for chronic pain.[26] In the hippocampus, μ-opioid activation increases the excitability of pyramidal neurons through both reducing GABAergic interneuron activity[43] and releasing astrocytic glutamate in the vicinity of pyramidal cells.[49] Consistent with the known effects of opioids on hippocampal excitability, we observed an increase in high-gamma amplitude in both anterior and posterior hippocampus. However, it was only beta oscillations, in anterior hippocampus specifically, which were associated with both opioid effects and pain relief. We are not aware of prior literature relating hippocampal beta oscillations to pain. However, beta may be particularly prominent

in the human hippocampal LFP, relative to that of model species.[33,46] In human intracranial recordings, enhanced beta oscillations have been observed during motor planning,[10] while increased beta coherence has been observed between hippocampus and amygdala during fear memory retrieval,[68] and between hippocampus, occipital cortex, and prefrontal cortex when recognizing known but highly distorted images,[61] suggesting that beta rhythms may be involved in internally generated mentation.

Similarly to the anterior hippocampus, we observed that opioids relatively increased beta power in medial amygdala and that this was associated with pain relief. We also observed evoked beta in individual medial amygdala sites (Fig. 3A), distinct from suppression in adjacent lateral sites. In the rodent amygdala, μ-opioid receptors produce inhibitory or disinhibitory effects, depending on the nucleus and cell type in question.[9,21,22] Rodent studies also indicate that the amygdala plays a role in pain-related affective responses,[67] and via reciprocal connections to medial prefrontal cortex and brainstem nuclei, could link nociception to protective behavioral and autonomic responses.[50] As a central mediator of fear and stress processes, the amygdala is implicated in the analgesia that attends fight-or-flight responses;[8,32] accordingly, stimulation of noradrenergic receptors in the amygdala of the rat induces analgesia in a thermally-evoked tail-flick test.[53] Interestingly, in the same model, the analgesic effects of morphine are attenuated with lesion or inactivation of the central amygdala,[40] suggesting that opioids may act through the amygdala pathway for stress-induced analgesia.

The present study includes a relatively small number of subjects; further, opioids were given in an uncontrolled clinical environment, where external factors may have varied between doses. Thus, the present results should be generalized with caution, and future research should attempt to replicate these findings utilizing prospective designs. Nevertheless, we included multiple controls for confounds and heterogeneity, to which our results were robust.

Overall, our results suggest a model in which opioidergic pain relief results from: (1) nociceptive gating (driven by amygdala and observed in reduced insular excitation); (2) decreased concerned fixation on pain (carried by reduced beta in VPFC); and (3) a shift toward internally generated experience (driven by the hippocampus). The current findings, though preliminary, provide a launching point for future investigation into the pathophysiology of clinical pain and strategies to combat it.

Data Availability

All data and analysis code underlying the study will be made available upon reasonable request, with the proviso that sharing of raw data in particular is subject to approval by the Institutional Review Board.

Acknowledgements

The authors express their sincere thanks to Syd Cash, Burke Rosen, Ilya Verzhbinsky, and Adam Niese for their contributions to this work.

Funding

This work was supported by National Institutes of Health grants no. T32MH020002 (J.C.G.), K08NS123543 (S.B.H.), and by a seed grant from the T. Denny Sanford Institute for Empathy and Compassion (J.C.G & E.H.).

Competing interests

The authors report no competing interests.

References

[1] Adler LJ, Gyulai FE, Diehl DJ, Mintun MA, Winter PM, Firestone LL. Regional Brain
     Activity Changes Associated with Fentanyl Analgesia Elucidated by Positron Emission
     Tomography. Anesth Analg 1997;84:120.

[2] Alves RL, Zortea M, Serrano PV, Brugnera Tomedi R, Pereira de Almeida R, Torres
     ILS, Fregni F, Caumo W. High-beta oscillations at EEG resting state and
     hyperconnectivity of pain circuitry in fibromyalgia: an exploratory cross-sectional study.
     Front Neurosci 2023;17. doi:10.3389/fnins.2023.1233979.

[3] Arnal LH, Giraud A-L. Cortical oscillations and sensory predictions. Trends Cogn Sci
     2012;16:390–398.

[4] Baliki MN, Chialvo DR, Geha PY, Levy RM, Harden RN, Parrish TB, Apkarian AV.
     Chronic Pain and the Emotional Brain: Specific Brain Activity Associated with
     Spontaneous Fluctuations of Intensity of Chronic Back Pain. J Neurosci
     2006;26:12165–12173.

[5] Baliki MN, Geha PY, Jabakhanji R, Harden N, Schnitzer TJ, Apkarian AV. A preliminary
     fMRI study of analgesic treatment in chronic back pain and knee osteoarthritis. Mol
     Pain 2008;4:47.

[6] Bastuji H, Frot M, Perchet C, Hagiwara K, Garcia-Larrea L. Convergence of sensory
     and limbic noxious input into the anterior insula and the emergence of pain from
     nociception. Sci Rep 2018;8:13360.

[7] Bastuji H, Frot M, Perchet C, Magnin M, Garcia-Larrea L. Pain networks from the
     inside: Spatiotemporal analysis of brain responses leading from nociception to
     conscious perception. Hum Brain Mapp 2016;37:4301–4315.

[8] Bellgowan PS, Helmstetter FJ. Neural systems for the expression of hypoalgesia during
     nonassociative fear. Behav Neurosci 1996;110:727–736.

[9] Blaesse P, Goedecke L, Bazelot M, Capogna M, Pape H-C, Jüngling K. μ-Opioid
     Receptor-Mediated Inhibition of Intercalated Neurons and Effect on Synaptic
     Transmission to the Central Amygdala. J Neurosci 2015;35:7317–7325.

[10] Caplan JB, Madsen JR, Schulze-Bonhage A, Aschenbrenner-Scheibe R, Newman EL, Kahana MJ. Human θ Oscillations Related to Sensorimotor Integration and Spatial Learning. J Neurosci 2003;23:4726–4736.

[11] Caston RM, Smith EH, Davis TS, Singh H, Rahimpour S, Rolston JD. Characterization of spatiotemporal dynamics of binary and graded tonic pain in humans using intracranial recordings. PLOS ONE 2023;18:e0292808.

[12] Chronux Home. n.d. Available: http://chronux.org/. Accessed 13 Nov 2024.

[13] Coda B, Tanaka A, C. Jacobson R, Donaldson G, Chapman CR. Hydromorphone analgesia after intravenous bolus administration. Pain 1997;71:41–48.

[14] Coghill RC, Sang CN, Maisog JMa, Iadarola MJ. Pain Intensity Processing Within the Human Brain: A Bilateral, Distributed Mechanism. J Neurophysiol 1999;82:1934–1943.

[15] Dahan A. Opioid chronopharmacology: influence of timing of infusion on fentanyl’s analgesic efficacy in healthy human volunteers. J Pain Res 2010:183.

[16] D'Argembeau A. On the Role of the Ventromedial Prefrontal Cortex in Self-Processing: The Valuation Hypothesis. Front Hum Neurosci 2013;7:372.

[17] Di Pietro F, Macey PM, Rae CD, Alshelh Z, Macefield VG, Vickers ER, Henderson LA. The relationship between thalamic GABA content and resting cortical rhythm in neuropathic pain. Hum Brain Mapp 2018;39:1945–1956.

[18] Dickey CW, Verzhbinsky IA, Jiang X, Rosen BQ, Kajfez S, Eskandar EN, Gonzalez-Martinez J, Cash SS, Halgren E. Cortical Ripples during NREM Sleep and Waking in Humans. J Neurosci 2022;42:7931–7946.

[19] Dickey CW, Verzhbinsky IA, Kajfez S, Rosen BQ, Gonzalez CE, Chauvel PY, Cash SS, Pati S, Halgren E. Thalamic spindles and Up states coordinate cortical and hippocampal co-ripples in humans. PLOS Biol 2024;22:e3002855.

[20] Dowman R, Darcey T, Barkan H, Thadani V, Roberts D. Human intracranially-recorded cortical responses evoked by painful electrical stimulation of the sural nerve. NeuroImage 2007;34:743–763.

[21] Faber ESL, Sah P. Opioids Inhibit Lateral Amygdala Pyramidal Neurons by Enhancing a Dendritic Potassium Current. J Neurosci 2004;24:3031–3039.

[22] Finnegan TF, Chen S-R, Pan H-L. Effect of the µ Opioid on Excitatory and Inhibitory Synaptic Inputs to Periaqueductal Gray-Projecting Neurons in the Amygdala. J Pharmacol Exp Ther 2005;312:441–448.

[23] Fischl B. FreeSurfer. NeuroImage 2012;62:774–781.

[24] Fischl B, van der Kouwe A, Destrieux C, Halgren E, Ségonne F, Salat DH, Busa E, Seidman LJ, Goldstein J, Kennedy D, Caviness V, Makris N, Rosen B, Dale AM. Automatically Parcellating the Human Cerebral Cortex. Cereb Cortex 2004;14:11–22.

[25] Frot M, Faillenot I, Mauguière F. Processing of nociceptive input from posterior to anterior insula in humans. Hum Brain Mapp 2014;35:5486–5499.

[26] Gagnon CM, Scholten P, Atchison J, Jabakhanji R, Wakaizumi K, Baliki M. Structural MRI Analysis of Chronic Pain Patients Following Interdisciplinary Treatment Shows Changes in Brain Volume and Opiate-Dependent Reorganization of the Amygdala and Hippocampus. Pain Med 2020;21:2765–2776.

[27] Garcia-Larrea L, Peyron R. Pain matrices and neuropathic pain matrices: A review. PAIN® 2013;154:S29–S43.

[28] Geha PY, Baliki MN, Chialvo DR, Harden RN, Paice JA, Apkarian AV. Brain activity for spontaneous pain of postherpetic neuralgia and its modulation by lidocaine patch therapy. Pain 2007;128:88–100.

[29] Glasser MF, Coalson TS, Robinson EC, Hacker CD, Harwell J, Yacoub E, Ugurbil K, Andersson J, Beckmann CF, Jenkinson M, Smith SM, Van Essen DC. A multi-modal parcellation of human cerebral cortex. Nature 2016;536:171–178.

[30] Grilli M. Chronic pain and adult hippocampal neurogenesis: translational implications from preclinical studies. J Pain Res 2017;Volume 10:2281–2286.

[31] Hashmi JA, Baliki MN, Huang L, Baria AT, Torbey S, Hermann KM, Schnitzer TJ, Apkarian AV. Shape shifting pain: chronification of back pain shifts brain representation from nociceptive to emotional circuits. Brain 2013;136:2751–2768.

[32] Helmstetter FJ, Bellgowan PS. Lesions of the amygdala block conditional hypoalgesia on the tail flick test. Brain Res 1993;612:253–257.

[33] Hirai N, Uchida S, Maehara T, Okubo Y, Shimizu H. Beta-1 (10–20 Hz) cortical oscillations observed in the human medial temporal lobe. NeuroReport 1999;10:3055.

[34] Hu L, Zhang L, Chen R, Yu H, Li H, Mouraux A. The primary somatosensory cortex and the insula contribute differently to the processing of transient and sustained nociceptive and non-nociceptive somatosensory inputs. Hum Brain Mapp 2015;36:4346–4360.

[35] Jones AKP, Friston KJ, Qi LY, Harris M, Cunningham VJ, Jones T, Feinman C, Frackowiak RSJ. Sites of action of morphine in the brain. The Lancet 1991;338:825.

[36] Kikinis R, Pieper SD, Vosburgh KG. 3D Slicer: A Platform for Subject-Specific Image Analysis, Visualization, and Clinical Support. In: Jolesz FA, editor. Intraoperative Imaging and Image-Guided Therapy. New York, NY: Springer, 2014. pp. 277–289. doi:10.1007/978-1-4614-7657-3_19.

[37] Levitt J, Edhi MM, Thorpe RV, Leung JW, Michishita M, Koyama S, Yoshikawa S, Scarfo KA, Carayannopoulos AG, Gu W, Srivastava KH, Clark BA, Esteller R, Borton DA, Jones SR, Saab CY. Pain phenotypes classified by machine learning using electroencephalography features. NeuroImage 2020;223:117256.

[38] Liberati G, Mulders D, Algoet M, van den Broeke EN, Santos SF, Ribeiro Vaz JG, Raftopoulos C, Mouraux A. Insular responses to transient painful and non-painful thermal and mechanical spinothalamic stimuli recorded using intracerebral EEG. Sci Rep 2020;10:22319.

[39] Machado AG, Baker KB, Plow E, Malone DA. Cerebral Stimulation for the Affective Component of Neuropathic Pain. Neuromodulation Technol Neural Interface 2013;16:514–518.

[40] Manning BH, Mayer DJ. The central nucleus of the amygdala contributes to the production of morphine antinociception in the rat tail-flick test. J Neurosci Off J Soc Neurosci 1995;15:8199–8213.

[41] Marple L. Computing the discrete-time "analytic" signal via FFT. IEEE Trans Signal Process 1999;47:2600–2603.

[42] Mazzola L, Faillenot I, Barral F-G, Mauguière F, Peyron R. Spatial segregation of somato-sensory and pain activations in the human operculo-insular cortex. NeuroImage 2012;60:409–418.

[43] McQuiston AR, Saggau P. Mu-opioid Receptors Facilitate the Propagation of Excitatory Activity in Rat Hippocampal Area CA1 by Disinhibition of all Anatomical Layers. J Neurophysiol 2003;90:1936–1948.

[44] Menon V, Uddin LQ. Saliency, switching, attention and control: a network model of insula function. Brain Struct Funct 2010;214:655–667.

[45] Mitra P. Observed Brain Dynamics. Oxford University Press, 2007.

[46] Moroni F, Nobili L, De Carli F, Massimini M, Francione S, Marzano C, Proserpio P, Cipolli C, De Gennaro L, Ferrara M. Slow EEG rhythms and inter-hemispheric synchronization across sleep and wakefulness in the human hippocampus. NeuroImage 2012;60:497–504.

[47] Motzkin JC, Hiser J, Carroll I, Wolf R, Baskaya MK, Koenigs M, Atlas LY. Human ventromedial prefrontal cortex lesions enhance the effect of expectations on pain perception. Cortex 2023;166:188–206.

[48] Mutso AA, Radzicki D, Baliki MN, Huang L, Banisadr G, Centeno MV, Radulovic J, Martina M, Miller RJ, Apkarian AV. Abnormalities in Hippocampal Functioning with Persistent Pain. J Neurosci 2012;32:5747–5756.

[49] Nam M-H, Won W, Han K-S, Lee CJ. Signaling mechanisms of μ-opioid receptor (MOR) in the hippocampus: disinhibition versus astrocytic glutamate regulation. Cell Mol Life Sci 2021;78:415–426.

[50] Neugebauer V. Amygdala Pain Mechanisms. In: Schaible H-G, editor. Pain Control. Berlin, Heidelberg: Springer, 2015. pp. 261–284. doi:10.1007/978-3-662-46450-2_13.

[51] Neumann N, Domin M, Schmidt C-O, Lotze M. Chronic pain is associated with less grey matter volume in the anterior cingulum, anterior and posterior insula and

hippocampus across three different chronic pain conditions. Eur J Pain 2023;27:1239–1248.

[52] Oertel B, Preibisch C, Wallenhorst T, Hummel T, Geisslinger G, Lanfermann H, Lötsch J. Differential Opioid Action on Sensory and Affective Cerebral Pain Processing. Clin Pharmacol Ther 2008;83:577–588.

[53] Ortiz JP, Heinricher MM, Selden NR. Noradrenergic agonist administration into the central nucleus of the amygdala increases the tail-flick latency in lightly anesthetized rats. Neuroscience 2007;148:737–743.

[54] Ostrowsky K. Representation of Pain and Somatic Sensation in the Human Insula: a Study of Responses to Direct Electrical Cortical Stimulation. Cereb Cortex 2002;12:376–385.

[55] Ploner M, Sorg C, Gross J. Brain Rhythms of Pain. Trends Cogn Sci 2017;21:100–110.

[56] Rosa MJ, Seymour B. Decoding the matrix: benefits and limitations of applying machine learning algorithms to pain neuroimaging. Pain 2014;155:864–867.

[57] Ryu S, Gwon D, Park C, Ha Y, Ahn M. Resting-state frontal electroencephalography (EEG) biomarkers for detecting the severity of chronic neuropathic pain. Sci Rep 2024;14:20188.

[58] Sakagami M, Pan X. Functional role of the ventrolateral prefrontal cortex in decision making. Curr Opin Neurobiol 2007;17:228–233.

[59] Schneider B, Koenigs M. Human lesion studies of ventromedial prefrontal cortex. Neuropsychologia 2017;107:84–93.

[60] Segerdahl AR, Mezue M, Okell TW, Farrar JT, Tracey I. The dorsal posterior insula subserves a fundamental role in human pain. Nat Neurosci 2015;18:499–500.

[61] Sehatpour P, Molholm S, Schwartz TH, Mahoney JR, Mehta AD, Javitt DC, Stanton PK, Foxe JJ. A human intracranial study of long-range oscillatory coherence across a frontal–occipital–hippocampal brain network during visual object processing. Proc Natl Acad Sci 2008;105:4399–4404.

[62] Shirvalkar P, Prosky J, Chin G, Ahmadipour P, Sani OG, Desai M, Schmitgen A, Dawes H, Shanechi MM, Starr PA, Chang EF. First-in-human prediction of chronic pain state using intracranial neural biomarkers. Nat Neurosci 2023;26:1090–1099.

[63] Silber MH, Ancoli -Israel Sonia, Bonnet MH, Chokroverty S, Grigg -Damberger Madeleine M., Hirshkowitz M, Kapen S, Keenan SA, Kryger MH, Penzel T, Pressman MR, Iber C. The Visual Scoring of Sleep in Adults. J Clin Sleep Med 2007;03:121–131.

[64] Simis M, Imamura M, Pacheco-Barrios K, Marduy A, De Melo PS, Mendes AJ, Teixeira PEP, Battistella L, Fregni F. EEG theta and beta bands as brain oscillations for different knee osteoarthritis phenotypes according to disease severity. Sci Rep 2022;12:1480.

[65] Stern J, Jeanmonod D, Sarnthein J. Persistent EEG overactivation in the cortical pain matrix of neurogenic pain patients. NeuroImage 2006;31:721–731.

[66] Vachon-Presseau E, Roy M, Martel M-O, Caron E, Marin M-F, Chen J, Albouy G, Plante I, Sullivan MJ, Lupien SJ, Rainville P. The stress model of chronic pain: evidence from basal cortisol and hippocampal structure and function in humans. Brain 2013;136:815–827.

[67] Veinante P, Yalcin I, Barrot M. The amygdala between sensation and affect: a role in pain. J Mol Psychiatry 2013;1:9.

[68] Wang D, Huang Z, Ren L, Liu J, Wang X, Yu T, Hu M, Wang X, Du J, Ni D, Zhang X, Gao R, Qiao L, Wang Y. Amygdalar and hippocampal beta rhythm synchrony during human fear memory retrieval. Acta Neurochir (Wien) 2020;162:2499–2507.

[69] Wiech K, Lin C, Brodersen KH, Bingel U, Ploner M, Tracey I. Anterior Insula Integrates Information about Salience into Perceptual Decisions about Pain. J Neurosci 2010;30:16324–16331.

[70] Wilkie DJ, Savedra MC, Holzemer WL, Tesler MD, Paul SM. Use of the McGill Pain Questionnaire To Measure Pain: A Meta-Analysis. Nurs Res 1990;39:36.

[71] Winston JS, Vlaev I, Seymour B, Chater N, Dolan RJ. Relative Valuation of Pain in Human Orbitofrontal Cortex. J Neurosci 2014;34:14526–14535.

[72] Zebhauser PT, Hohn VD, Ploner M. Resting-state electroencephalography and magnetoencephalography as biomarkers of chronic pain: a systematic review. Pain 2023;164:1200–1221.

Figures

Figure 1. Intravenous opioids produce characteristic amplitude suppression in beta frequencies. A. Event-related spectral perturbation (ERSP) relative to recorded drug administration time. Each frequency is normalized to average amplitude during -30 to -10 minute baseline. Hydromorphone (top, middle) produces a longer duration suppression of beta amplitude as compared to fentanyl (bottom), as expected due to the longer kinetics of hydromorphone. **B.** Post-drug (10-30 minute average) power spectra normalized to pre-drug baseline. Shaded area indicates SEM. Each plot shows a different site from the same subject as the adjacent ERSP (A). All shown sites exhibited significantly (p<0.05 FDR) suppressed beta analytic amplitude during the 10 to 30 minute peak effect period, relative to -30 to 10 min baseline.

Figure 2. Beta amplitude modulation by intravenous opioids. A. Mean (SEM) beta amplitude over channels and trials, relative to opioid doses. Opioid-evoked beta modulation was calculated as the mean difference between post-drug (cyan) and baseline (green) periods. Orange traces correspond to fentanyl and purple traces correspond to hydromorphone. All traces significant (p<0.05 FDR corrected). **B.** Same as A but for example sites. All traces significant (p<0,.05 FDR corrected). **C.** All sites color-coded according to beta amplitude modulation. Overall, opioids tended to reduce beta amplitude. Beta suppression was most profound in prefrontal cortex, including VPFC and DLPFC, and in insular cortex. **D.** Distributions of modulation values for various categories of site. Fentanyl and hydromorphone similarly suppressed beta amplitude, and left hemisphere sites showed somewhat more beta suppression than right hemisphere sites.

Figure 3. Modulation of beta amplitude in medial temporal lobe by intravenous opioids.
A. Opioid-locked beta amplitude from sites corresponding to a single medial-lateral trajectory through right amygdala, showing a strong gradient in direction and time-course of response. Lateral amygdala exhibits strong suppression of beta amplitude developing by 10 minutes and abating within an hour post-drug, similarly to responses observed in cortical regions. In contrast, medial amygdala shows a transient beta amplification 5-10 minutes post-drug (p=0.004, 0.005, 0.027, FDR corrected, post-hoc). **B.** Coregistered MRI/CT showing locations of sites (bipolar pairs) represented in A. **C.** All sites in medial temporal structures. Across all sites, lateral amygdala tended to show cortex-like beta suppression, whereas medial amygdala showed inconsistent responses during the 10-30 minute post-drug epoch. Hippocampus, both anterior and posterior, displayed generally evoked beta amplitude increases or no response, in stark contrast to the suppression seen in cortex and Lateral Amygdala.

Figure 4. High-gamma amplitude modulation by intravenous opioids. A. Mean (SEM) high-gamma amplitude relative to opioid doses for example sites. Opioid-evoked HG modulation was calculated as the mean difference between post-drug (cyan) and baseline (green) periods. Evoked changes in high-gamma amplitude vary widely in direction and time-course. * Indicates significance of the individual site (p<0.05 FDR over all sites). **B.** All sites color-coded according to high-gamma amplitude modulation. High-gamma amplitude decreased in Insula and Lateral Amygdala, while increases were present in Cingulate, AHC, and PHC (See table 2). **C.** Distributions of modulation values for various categories of site. Mean increases and decreases were present to similar degrees (no overall average effect). Sites in subjects that received fentanyl tended to exhibit slightly lower post-drug high-gamma amplitude than those in hydromorphone subjects.

Figure 5. Site-wise correlations between beta and high-gamma amplitude and pain relief. A. Correlations (R-values) in medial temporal sites for 15-25 Hz beta (top) and 70-190 Hz high-gamma (bottom) versus pre-to-post-drug pain relief. **B.** Equivalent correlations to A in cortical sites. See table 2 for region-wise correlation and significance values, and **Materials and methods, Site-wise pain-relief correlation estimates** computation of site-wise R-values, and **Cross-site drug effects and pain relief models** for region-wise statistical modeling.

Figure 6. Variation of drug effects and pain-relief correlations in beta and high-gamma amplitude, along a cortical-to-limbic axis. Beta and high-gamma amplitude (red lines) are strongly suppressed in cortical structures including VPFC, Insula, and (beta only) DLPFC. Limbic structures (Anterior and Posterior HC, Medial Amygdala) show relative increases in beta/high-gamma amplitude, with the exception of Lateral Amygdala which shows suppression similarly to cortical areas. Correlations with pain relief (green lines) are seen exclusively in regions associated with pain or affect: VPFC, Insula, Medial Amygdala, Anterior HC. In each of these regions, either beta or high-gamma effects of opioids would be predicted to relieve pain.

Tables

Subject	Age	Sex	Days	Drug	N Doses	N Doses (Pain analysis)	Dose (mode)	N Sites	Median (Range) VAS
S1	36-40	M	10.7	Fentanyl	22	14	50 mcg	25	5 (0-10)
S2	21-25	F	9.0	Fentanyl	33	21	12.5 mcg	21	4 (0-9)
S3	31-35	M	13.0	Hydro-morphone	51	29	1 mg	29	7 (0-10)
S4	31-35	M	15.0	Hydro-morphone	14	8	0.5 mg	41	5.5 (0-10)

Table 1. Subject characteristics.

Drug Effect	Coefficient (z-score)		p-value	
Model Term	Beta	HG	Beta	HG
Main Effect	**-0.47**	-0.01	7.1E-14	0.86
DLPFC	**-0.47**	0.14	6.9E-06	0.39
VPFC	**-0.38**	-0.25	0.02	0.35
Parietooccipital	0.23	-0.07	0.24	0.82
Insular	-0.09	**-0.49**	0.53	0.03
Lat. Temporal	0.04	-0.25	0.78	0.24
Cingulate	0.18	**0.42**	0.13	0.03
Uncus	-0.14	-0.27	0.53	0.44
Lat. Amygdala	**-0.86**	**-0.55**	8.4E-07	0.04
Med. Amygdala	**0.33**	-0.18	0.04	0.48
Anterior HC	**0.61**	**0.58**	1.4E-04	0.02
Posterior HC	**0.85**	**0.67**	1.5E-07	5.7E-03
Hemisphere (LH)	**-0.13**	**-0.23**	0.01	0.01
Drug (Hydro.)	0.02	**0.28**	0.69	5.9E-03
Pain Relief	Coefficient (R-value)		p-value	
Model Term	Beta	HG	Beta	HG
Main Effect	**-0.10**	-0.03	0.01	0.40
DLPFC	0.00	0.06	0.97	0.38
VPFC	**-0.24**	**-0.24**	0.04	0.05
Parietooccipital	0.10	-0.04	0.47	0.76
Insular	-0.12	**-0.32**	0.19	2.0E-03
Lat. Temporal	-0.13	0.09	0.17	0.38
Cingulate	-0.14	0.11	0.11	0.21
Uncus	-0.03	0.13	0.86	0.40
Lat. Amygdala	0.11	0.11	0.32	0.37
Med. Amygdala	**0.38**	**0.36**	5.6E-04	2.4E-03
Anterior HC	**0.25**	0.17	0.02	0.14
Posterior HC	0.03	-0.07	0.77	0.54
Hemisphere (LH)	0.01	0.25	0.78	0.52
Drug (Hydro.)	-0.05	**-0.09**	0.16	0.02
Key	negative, not sig.		not sig.	
	+, drug or pain sig.		drug or pain sig.	
	-, drug and pain sig.		drug and pain sig.	

Table 2. Linear mixed-effects model coefficients for evoked drug effects and pain-relief correlations in beta and high-gamma amplitude. Negative values (red) indicate that decreases were related to drug effect (top) or pain relief (bottom) and significant coefficients are bolded. Opioids decreased beta amplitude overall, but did so particularly in prefrontal cortex (VPFC and DLPFC) and Lateral Amygdala; in VPFC this decrease was concordant with pain relief. In other structures of medial temporal lobe, opioids increased beta in relative

(Med. Amyg.) and absolute (Ant. and Pos. HC) terms; this aligns with pain relief in Med. Amyg. and Ant. HC. High-gamma was suppressed by opioids in Insular Cortex, matching pain relief in that structure, while in Cingulate Cortex, opioid-evoked high-gamma contrasts with expected lower high-gamma amplitude during pain relief.